Chong Kun Dang Pharmaceutical Corp
KRX:185750
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
94 000
133 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Chong Kun Dang Pharmaceutical Corp
Chong Kun Dang Pharmaceutical Corp
Accrued Liabilities
Chong Kun Dang Pharmaceutical Corp
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chong Kun Dang Pharmaceutical Corp
KRX:185750
|
Accrued Liabilities
₩27.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Accrued Liabilities
₩37.5B
|
CAGR 3-Years
213%
|
CAGR 5-Years
36%
|
CAGR 10-Years
48%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Accrued Liabilities
₩71.3B
|
CAGR 3-Years
25%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Accrued Liabilities
₩55.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Accrued Liabilities
₩10.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Accrued Liabilities
₩313m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-17%
|
|
Chong Kun Dang Pharmaceutical Corp
Glance View
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-12-06. The firm is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The firm sells products in domestic and overseas markets.
See Also
What is Chong Kun Dang Pharmaceutical Corp's Accrued Liabilities?
Accrued Liabilities
27.5B
KRW
Based on the financial report for Dec 31, 2023, Chong Kun Dang Pharmaceutical Corp's Accrued Liabilities amounts to 27.5B KRW.
What is Chong Kun Dang Pharmaceutical Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
6%
Over the last year, the Accrued Liabilities growth was 38%. The average annual Accrued Liabilities growth rates for Chong Kun Dang Pharmaceutical Corp have been 26% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
